Specialty Pharma Journal Specialty, Precision & Technology
Mechelen, Belgium, 29 November 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces it has entered into an agreement with AstraZeneca, a global science-led biopharmaceutical company (LON: AZN), aimed at obtaining faster lung cancer molecular diagnostic biomarker results in Europe. …
Tag Archives: lung cancer
November, 2018
-
16 November
AstraZeneca Provides Update on the Phase 3 Trial of Imfinzi and tremelimumab in Stage IV Non-Small Cell Lung Cancer
AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) platinum-based chemotherapy in previously-untreated patients with Stage IV …
-
5 November
FDA Approves Pfizer’s Lorbrena for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one …
-
1 November
FDA Approves Merck’s Keytruda in Combination with Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell …
October, 2018
-
24 October
Genentech’s Tecentriq Plus Chemotherapy as Initial Treatment Helped Advanced Non-Squamous NSCLC Patients Live Significantly Longer than Chemotherapy Alone
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower130 study of Tecentriq® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer …
-
15 October
Bristol-Myers Squibb’s Opdivo Fails to Meet Primary Endpoint in Phase 3 Study in Patients with Relapsed Small Cell Lung Cancer
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. The study did not meet its primary endpoint of …
September, 2018
-
28 September
FDA Approves Pfizer’s Vizimpro for First-Line Treatment of EGFR-Mutated Metastatic NSCLC
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution …
-
25 September
Genentech’s Tecentriq Plus Chemo Significantly Improved Overall Survival in Extensive-Stage Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower133 study of TECENTRIQ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). The analysis …
-
25 September
Imfinzi is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung …
August, 2018
-
30 August
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) — A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer (NSCLC). Researchers utilized samples from the Phase 3 MARQUEE trial and found that the VeriStrat (VS) test was a significant predictor of outcomes, independent …